In line with these experimental data, emerging clinical trial results in human psoriasis (PsO) indicate that not only IL-17A blockade (8, 9) but also blockade of the p40 (10) or the p19 (11–13) subunit of IL-23 is highly effective. This evidence concerns the gene IL23A and psoriasis.